JAK2 and Eczematoid dermatitis: In contrast to the model group, SYXL (300, 900 μg/mL) inhibited the phosphorylation of JAK2 and STAT3, suggesting that suppression of JAK/STAT pathway activation may represent a key mechanism underlying SYXL’s anti-inflammatory and anti-eczema properties.